Hydrochlorothiazide Side Effects
Hydrochlorothiazide causes dose-related electrolyte disturbances (hypokalemia, hypomagnesemia, hyponatremia), metabolic abnormalities (hyperglycemia, hyperuricemia), and carries an increased risk of non-melanoma skin cancer with chronic use.
Electrolyte and Metabolic Disturbances
The most clinically significant adverse effects are electrolyte abnormalities, which occur in a dose-dependent manner:
Hypokalemia (serum potassium <3.5 mmol/L) occurs in approximately 12.6% of hydrochlorothiazide users, affecting roughly 2 million US adults 1. At doses of 25 mg or greater, hypokalemia risk increases substantially 2. Women, non-Hispanic blacks, underweight patients, and those on long-term therapy (≥5 years) face higher risk 1.
Hypomagnesemia and hyponatremia are common, particularly at doses ≥25 mg daily 3, 4. These electrolyte disturbances can predispose patients to serious cardiac arrhythmias, especially when combined with digitalis 5.
Hyperglycemia and glucose intolerance occur with thiazide therapy, though the clinical impact is modest. In ALLHAT, chlorthalidone (a related thiazide-like diuretic) increased fasting glucose by only 1.5-4.0 mg/dL without translating to increased cardiovascular risk 6, 7.
Hyperuricemia develops in many patients, though gout is uncommon at doses ≤50 mg/day 2. The mechanism involves volume contraction and competition with uric acid for renal tubular secretion 8.
Cardiovascular and Hemodynamic Effects
Orthostatic hypotension can occur, particularly when combined with alcohol, barbiturates, narcotics, or other antihypertensive agents 4. This risk is especially relevant in elderly patients, who should start with the lowest dose (12.5 mg) 4.
Serious Adverse Reactions (Rare but Important)
The FDA label 4 lists severe reactions that, while uncommon, require immediate recognition:
- Hematologic: Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia
- Hypersensitivity: Anaphylactic reactions, necrotizing angiitis (vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity 4, 9, 10
- Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis 4, 9
- Renal: Renal failure, renal dysfunction, interstitial nephritis 4
- Gastrointestinal: Pancreatitis, jaundice (intrahepatic cholestatic) 4
Non-Melanoma Skin Cancer Risk
Hydrochlorothiazide significantly increases the risk of non-melanoma skin cancer, particularly squamous cell carcinoma (SCC), with chronic use 4. The risk is dose-dependent and predominantly affects white patients. At cumulative doses ≥50,000 mg, there is approximately 1 additional SCC case per 6,700 white patients per year 4.
Other Common Side Effects
At doses ≥25 mg daily 4:
- Gastrointestinal: Nausea, vomiting, diarrhea, constipation, gastric irritation, cramping
- Neurologic: Dizziness, vertigo, headache, paresthesias
- Musculoskeletal: Muscle spasm
- Genitourinary: Impotence (though this remains controversial as a diuretic-specific effect 8)
- Ophthalmologic: Transient blurred vision, xanthopsia
Critical Monitoring Requirements
All patients on hydrochlorothiazide require electrolyte monitoring shortly after initiation and periodically thereafter 11. This is particularly crucial when:
- Combining with other diuretics (markedly enhances electrolyte depletion risk 5)
- Using with ACE inhibitors or ARBs (can cause hyperkalemia in patients with CKD, diabetes, or heart failure 12)
- Prescribing to high-risk populations (elderly, those on long-term therapy, women, ethnic minorities 1)
Important caveat: Even among patients taking potassium supplements, 27.2% on monotherapy and 17.9% on polytherapy still develop hypokalemia 1, indicating that supplementation alone is insufficient protection.
Drug Interactions to Avoid
- NSAIDs (including COX-2 inhibitors): Block diuretic effects and can precipitate renal dysfunction 5, 4
- Lithium: Diuretics reduce lithium clearance and greatly increase toxicity risk—generally should not be combined 4
- Cholestyramine/colestipol: Reduce hydrochlorothiazide absorption by 43-85% 4
Comparative Safety Profile
Hydrochlorothiazide causes fewer metabolic side effects than chlorthalidone (lower rates of hypokalemia, hyponatremia, hypomagnesemia) 12, 13, though chlorthalidone remains more potent for blood pressure reduction 8, 13. Fixed-dose combination therapy with potassium-sparing agents reduces hypokalemia risk by 68% compared to monotherapy 1.